Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer: the BRANCH Trial
To determine the pathological complete response (pCR-TRG1) rate in patients treated with 2
different schedule of bevacizumab plus primary chemotherapy and radiotherapy of the pelvic
region when optimal surgery is applied.
Bevacizumab will be given by intravenous infusion at the dose of 5 mg/kg concurrent with
chemotherapy and radiotherapy every 2 weeks for 4 cycles from -14 days to start
chemo-radiotherapy (classical schedule) or 4 days before the concurrent administration of
chemotherapy and radiation therapy for 2 cycles if the number of TRG1 was not reached in the
first stage with the classical schedule Simon's methods will be used to calculate sample
size.Setting a and b errors as 0.05 and 0.20, respectively, and defining as minimum activity
of interest (p0) a TRG1 rate=30%. In order to demonstrate a TRG1 rate ≥50% (p1), at least 6
TRG1 on the first 15 patients, and at least 19 TRG1 on a total of 46 patients should be
reported in the first and second stage, respectively.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
complete tumor regression rate (TRG1)
complete tumor regression rate(TRG1) with tumor regression graded at at surgical resection at 8 weeks after completion of chemoradiotherapy
within 8 weeks after completion of chemoradiotherapy
No
Antonio Avallone, M.D.
Principal Investigator
National Cancer Institute, Naples
Italy: Ethics Committee
BRANCH
NCT01481545
December 2006
January 2014
Name | Location |
---|